Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday

U.S. stocks closed lower, with the Dow Jones down over 150 points, as several companies experienced sharp declines following specific corporate news. Freeport-McMoRan (FCX) shares plunged 16.4% after issuing third-quarter sales guidance and reporting a fatal mine incident. Harmony Biosciences (HRMY) also dropped 14.6% following the failure of its Phase 3 clinical trial for ZYN002 to meet its primary endpoint, with Cohu (COHU) and Worthington Enterprises (WOR) also seeing significant losses on convertible note offerings and Q1 results, respectively.

Analysis

The U.S. market exhibited bearish sentiment, evidenced by the Dow Jones index's 150-point decline, but the session was primarily characterized by significant, idiosyncratic stock movements driven by negative corporate-specific catalysts. Freeport-McMoRan (FCX) was a notable decliner, with its shares falling 16.4% to $37.94. This sharp drop was precipitated by a dual shock: the release of third-quarter sales guidance, which the market reaction suggests was disappointing, and a severe operational disruption involving a fatal mud rush incident at its Grasberg mine. In the biotechnology sector, Harmony Biosciences (HRMY) plunged 14.6% after its Phase 3 clinical trial for ZYN002 failed to meet its primary endpoint, a significant setback for its pipeline that was amplified by a Needham price target cut from $48 to $41. Other notable losses were driven by financing activities and earnings, with Cohu (COHU) falling 12.7% after announcing a convertible senior notes offering, which implies potential shareholder dilution, and Worthington Enterprises (WOR) dropping 11.3% following its first-quarter results, indicating a substantial miss on market expectations.

Key Decisions for Investors

• Investors in Freeport-McMoRan (FCX) should immediately reassess their position, as the combination of potentially weak forward guidance and a material operational and ESG event at a key asset introduces significant uncertainty to its production outlook and cost structure.
• The failure of Harmony Biosciences' (HRMY) Phase 3 trial for ZYN002 requires a fundamental re-evaluation of the company's valuation, which must now be based on its remaining commercial products and earlier-stage pipeline assets, as a major growth driver has been eliminated.
• The negative market reactions to Cohu's (COHU) convertible note offering and Worthington's (WOR) earnings miss signal a low tolerance for dilutive financing and performance shortfalls; investors should scrutinize company balance sheets and upcoming earnings reports for similar vulnerabilities.
• Given the numerous sharp declines on company-specific news, portfolio managers should exercise caution with positions that have near-term catalysts such as clinical trial readouts or earnings announcements, as the market is punishing negative surprises severely.